Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025
Abstract
Hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for approximately two-thirds of all breast cancers. The treatment landscape for HR+/HER2- metastatic breast cancer has evolved in recent years, with multiple new therapies demonstrating clinical efficacy and improved patient outcomes. To provide evidence-informed guidance on best practices in the management of patients with HR+/HER2- metastatic breast cancer in Canada, consensus recommendations were developed by Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance), a standing nucleus committee with both clinical-academic oncologists from across Canada and representatives from Breast Cancer Canada, a patient advocacy organization. Recommendations were generated using a modified Delphi approach involving up to three anonymous voting rounds, with a predefined consensus threshold of 75%. These consensus recommendations offer guidance on optimal therapeutic strategies for HR+/HER2- metastatic breast cancer within the Canadian landscape, including integration of precision oncology and targeted therapies, optimal sequencing of therapies, and the importance of balancing the benefits of treatments with patient quality of life and preferences.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.